Researchers sign-up to keep up-to-date on funding opportunities, activities and Epilepsy Foundation events.

Letter of Intent due: July 21, 2017, 11:59 PM ET

If LOI is accepted, APPLICATION is due: September 25, 2017, 11:59 PM ET


The mission of the New Therapy - Commercialization Grants Program is to drive the development of new therapies for epilepsy, accelerating the advancement of research from the laboratory to the patient. Funding is provided to academic and commercial groups worldwide. The Program seeks to advance the development of new therapies including but not limited to medicines, biologics or devices. All proposals must demonstrate a clear path from the lab to the patient and are evaluated with consideration for their potential value to patients, likelihood of successful development including regulatory approval and the timeframe of development. The Program also encourages 1:1 matching grants to academic and commercial entities to support the commercialization of novel approaches to the treatment of epilepsy. Preference will be given to proposals that already have a commercial partner engaged to assist with development, and to proposals that have committed or matched funding from a sponsoring institution, commercial partner or other third party source.

New Therapy - Commercialization Grants Program

Applicants must demonstrate background work beyond the basic science discovery stage.

Areas of interest include:

  • Novel approaches to treatment.

  • Platform technology to advance screening techniques that can be utilized by multiple laboratories, including utility of techniques for early proof-of-concept trials.

  • Adaptation of treatment in development for another therapeutic area to assess utility for epilepsy (while maintaining patent protection).

All proposals will be evaluated by our Business and Scientific Advisory Boards, as described below:

Proposals are rated on the likelihood of success by the Business Advisory Board as:

  1. Intellectual Property Strategy & Status; Freedom To Operate

  2. Can this Get to Patients: Investment Potential & Likelihood of Ongoing Funding Support

  3. Probability of Success / Time Factor

  4. Fit with Program Mission / Patient Impact

  5. Overall Impression

Proposals are rated on the likelihood of success by the Scientific Advisory Board as:

  1. Quality of Science

  2. Probability of Successful completion of milestones / outlined program

  3. Timeframe of Success

  4. Fit with Program Mission / Impact on Patients

  5. Overall Impression

These grants are awarded primarily to programs that have progressed beyond the basic science discovery stage. Programs that seek to develop potential drugs should have identified at least one lead compound, which may be at the pre-IND stage, in order to be competitive for a New Therapy Commercialization Grant. Investigators of drugs are strongly advised to have their compounds screened, as appropriate, by the NINDS ETSP Program. Investigators are expected to have an established record of achievement in the area. Full intellectual property (IP) rights (composition of matter) are preferred over method of use IP.

Clinical programs must have a reasonable protocol and sample size to assure that the results will be meaningful; studies of patients should describe the type of seizure/epilepsy that will be investigated. Investigators proposing a clinical trial should include the protocol in the application materials. If another entity, such as a pharmaceutical company, is providing partial funding support or in-kind contribution to the study (such as study drug and/or placebo), please provide a letter of support detailing the agreed-upon funding or resources provided. Device programs should present novel concepts for treatment. Applicants should apply for the amount needed to complete the project or the project phase, however, please note that in general the NTCG program does not award budgets that exceed $350,000 over a two-year period. Applicants for the Seal Award should include information on the total amount needed to complete the project.  Detailed budgets are strongly encouraged.

Confidential information should NOT be sent to the Epilepsy Foundation or provided in any grant application without advance discussion with the Epilepsy Foundation and only with appropriate confidentiality agreements.

Scientific questions about appropriateness of an application should be directed to Brandy Fureman,

Investigators must submit a Letter of Intent by July 21, 2017 by 11:59 pm ET.
The deadline for receipt of full Grant proposals is September 25, 2017 by 11:59 pm ET.
Full proposals will be accepted only from Investigators whose Letter of Intent was approved.

How to Apply